Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.
It is generally thought that there is full cross-resistance in Mycobacterium tuberculosis between the aminoglycoside drugs kanamycin and amikacin. However, kanamycin resistance and amikacin susceptibility were seen in 43 of 79 (54%) multidrug-resistant Estonian isolates, indicating that there might be a need to test the resistance of M. tuberculosis isolates to both drugs.
Krüüner
Annika
A
Department of Bacteriology, Swedish Institute for Infectious Disease Contro, Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden. annika.kruuner@kliinikum.se
Jureen
Pontus
P
Levina
Klavdia
K
Ghebremichael
Solomon
S
Hoffner
Sven
S
D000583:Amikacin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D004957:Estonia; D005798:Genes, Bacterial / Q000235:genetics; D005838:Genotype; D007612:Kanamycin / Q000494:pharmacology*; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics; D012150:Polymorphism, Restriction Fragment Length; D014376:Tuberculosis / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D007612:Kanamycin; D000583:Amikacin